Need professional-grade analysis? Visit stockanalysis.com
$1.61B
N/A
N/A
N/A
Damora Therapeutics, Inc. (DMRA) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $26.82, up 0.83% from the previous close.
Over the past year, DMRA has traded between a low of $18.14 and a high of $28.91. The stock has lost 5.4% over this period. It is currently 7.2% below its 52-week high.
Damora Therapeutics, Inc. has a market capitalization of $1.61B.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Side-by-side comparison against top Healthcare peers.